Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

ProMed Pharma begins preclinical testing of resorbable contraceptive implant

By Brian Buntz | April 20, 2022

ProMedAfter receiving funding from the Bill & Melinda Gates Foundation, ProMed Pharma has begun preclinical evaluation of a novel fully resorbable contraceptive implant.

The Plymouth, Minnesota–based company imagines that the contraceptive implants could ultimately find use in low- and middle-income (LMIC) settings.

The novel implant potentially could offer women 18 months of contraception through the long-term release of levonorgestrel, a hormonal type of birth control first patented in 1960.

The fully biodegradable implant would also obviate the need for women to travel to medical clinics to have the device removed.

In addition, the device is designed to enable physicians to remove the device early, if needed.

A contract manufacturer of polymer-based drug releasing implantable silicone components,

contraceptive implant

Novel bioresorbable contraceptive implant developed at ProMed Pharma

ProMed has selected four lead formulations of the birth-control product candidate combining levonorgestrel with commercially available biopolymers.

“The implant designs have shown promising mechanical integrity and drug release profiles based on in vitro tests to date and have a form factor which is similar if not superior to other implants on the market,” said Dr. James Arps, director of business development at ProMed, in a press release.

ProMed plans on spending at least six months on the preclinical study and could potentially collect drug release and polymer degradation data up to 1.5 years.

Tell Us What You Think! Cancel reply

Related Articles Read More >

World Changing Ideas
Fast Company 2022 World-Changing Ideas Awards highlight multiple pharma innovations
Pfizer logo
Pfizer appoints new chief financial officer
Pfizer logo
Pfizer donates Russian profits to Ukraine
Novartis logo
Novartis partners with Carisma Therapeutics on manufacturing HER2-targeted CAR-M cell therapy

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards